(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.32%) $78.73
(-1.64%) $2.16
(0.13%) $2 334.30
(-0.05%) $27.60
(0.40%) $968.80
(0.06%) $0.929
(0.18%) $10.84
(0.04%) $0.796
(0.00%) $91.35
0.00% € 0.000200
Live Chart Being Loaded With Signals
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction...
Stats | |
---|---|
Dzisiejszy wolumen | 129.10M |
Średni wolumen | 104.90M |
Kapitalizacja rynkowa | 1.48M |
EPS | €0 ( 2024-04-05 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 0 |
ATR14 | €0 (0.00%) |
Oxurion NV Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Oxurion NV Finanse
Annual | 2023 |
Przychody: | €263 000 |
Zysk brutto: | €104 000 (39.54 %) |
EPS: | €-0.0115 |
FY | 2023 |
Przychody: | €263 000 |
Zysk brutto: | €104 000 (39.54 %) |
EPS: | €-0.0115 |
FY | 2022 |
Przychody: | €595 000 |
Zysk brutto: | €-271 000 (-45.55 %) |
EPS: | €-0.370 |
FY | 2021 |
Przychody: | €1.13M |
Zysk brutto: | €516 000 (45.74 %) |
EPS: | €-0.928 |
Financial Reports:
No articles found.
Oxurion NV
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej